Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.

Nabsys 2.0, LLC ("Nabsys"), a pioneer in Electronic Genome Mapping (EGM), today announced the publication of a new preprint ...

With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for ...

Clayface 2026 opens Oct. 23 as DC Studios' first R-rated horror film. The villain's serum -- a treatment that corrects one tissue while catastrophically rewriting all others -- is a scaled-up version ...

CRISPR Therapeutics stock trades around USD 56.56 as of September 20, 2026, after a volatile year for gene-editing biotech ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...

CRISPR may be a powerful technology for gene editing, but the system existed in bacteria long before scientists began using it. For billions of years, CRISPR has acted as a natural immune system in ...

Editing a plant's genes is only half the battle. Before a new, improved trait can ever reach a farmer's field, scientists ...

CRISPR Therapeutics stock has climbed in the shorter term but still carries a heavy five year loss, and current valuation checks point to a company that does not clearly screen as either cheap or ...

CRISPR Therapeutics (CRSP) is drawing fresh attention as investors digest management’s recent comments on faster CASGEVY ...

Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...

For farmers and consumers to reap the benefits, guidelines for farming gene-edited plants must be implemented with careful thought.